Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Like most of its peers in the biopharma sector, Genentech has been working on AI-powered technologies for drug discovery and development, coming up with a proprietary set of algorithms and other ...

Genentech started working on PI3K nearly two decades ago ... “If we can add a PI3K-mutation drug to first-line therapy,” ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

Genentech, a drug company, makes bevacizumab, ranibizumab, and faricimab. This company helps patients cover the cost of their products through the Genentech Patient Foundation. If you have ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and ...

I’d like to think that Genentech and many other companies in our industry are starting to follow that approach. *This program requires pharmaceutical manufacturers in Medicaid to sell drugs at ...